Christine E. Horak
168 works · 36,296 citations · h-index 46
Top works
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- Genomic binding sites of the yeast cell-cycle transcription factors SBF and MBF
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
- Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
- Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.
- Complex transcriptional circuitry at the G1/S transition in Saccharomyces cerevisiae
- GATA-1 binding sites mapped in the β-globin locus by using mammalian chIp-chip analysis
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- ChIP-chip: A genomic approach for identifying transcription factor binding sites
- Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma
- MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
- Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer